EGFR and non-small cell lung carcinoma: For instance, Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI) has been approved by the U.S. Food and Drug Administration for treatment of metastatic NSCLC patients with EGFR T790M mutation [4] which accounts for acquired resistance in 50%–60% of the patients who received first- and second-generation EGFR TKIs treatment [3, 5].